ESC 365 - Standard and reduced doses of dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study

ESC Premium Access

Standard and reduced doses of dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study

Session: Young Investigator Awards Session Thrombosis

Topic: Atrial fibrillation (AF)

Speaker: Doctor L. Staerk (Hellerup, DK)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Doctor Laila Staerk

Gentofte Hospital - Copenhagen University Hospital, Hellerup (Denmark)

0 follower

3 more presentations in this session

Impact on clinical outcome of on-treatment platelet reactivity according to concordant platelet function tests: the multi-test platelet function study

Speaker: Doctor P. Guedeney (Paris, FR)

A meta-analysis of INR targets for mechanical heart valves: we need new evidence

Speaker: Doctor S. Gupta (Edmonton, CA)

Thrombin Exosite 1 Inhibition with JNJ-375 Inhibits Fibrin-Rich Thrombus Formation in a Human Translational Model of Thrombosis

Speaker: Doctor S. Wilson (Edinburgh, GB)

Access the full session

Young Investigator Awards Session Thrombosis

Speakers: Doctor L. Staerk, Doctor P. Guedeney, Doctor S. Gupta, Doctor S. Wilson

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources